Clinical Trial Update: A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is investigating Sonrotoclax alone and in combination with Zanubrutinib in adults with Waldenström macroglobulinemia; the study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Sonrotoclax
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: BeOne Medicines | Conditions: Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent | Phase 2 | Status: ACTIVE_NOT_RECRUITING